JAK Inhibition in Rheumatoid Arthritis
|
|
- Jennifer Dennis
- 5 years ago
- Views:
Transcription
1 Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including sponsor and supporter, disclosures, and instructions for claiming credit) are available by visiting: Released: 10/29/2018 Valid until: 10/29/2019 Time needed to complete: 15 minutes ReachMD info@reachmd.com (866) JAK Inhibition in Rheumatoid Arthritis Announcer This is CME on ReachMD! You re listening to Updates in Autoimmunity and Chronic Inflammatory Disorders: Think You Know JAK? The following activity will discuss JAK inhibition in rheumatoid arthritis. This activity is jointly provided by Global Education Group and Integritas Communications, and supported by an independent educational grant from Gilead Sciences, Inc. Before beginning this activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives. Dr. Allan Gibofsky Hello, and welcome to this program, in which we will look at autoimmunity in rheumatoid arthritis [RA], focusing on the JAK [Janus kinase] pathway. I m Dr. Allan Gibofsky, attending physician at the Hospital for Special Surgery, and Professor of Medicine and Public Health at Weill Cornell Medical College in New York City. I m joined today by Dr. Joel Kremer, Professor of Medicine at Albany Medical College, 2018 ReachMD Page 1 of 7
2 and Director of Research at the Center for Rheumatology in Albany, New York. In this program, we will discuss targeted synthetic DMARDs [disease-modifying antirheumatic drugs] that inhibit members of the Janus kinase family of enzymes (or JAK inhibitors) as treatment options for patients with rheumatoid arthritis. Joel, let s begin with a brief discussion of how we should structure the treat-to-target concept in the context of what, as you and I have discussed so many times, is a mechanistically heterogeneous disease. Dr. Joel Kremer I think you and I feel passionate about treating to target. Why settle for moderate disease if you can get the patient to low disease, because there are a lot of comorbidities and implications with poor control. So why not treat to target? And the answer is, there is no good reason. Almost half the time, patients who do not have adequately controlled disease will say, Doc, I m not ready to accelerate treatment. Now, I think if we just talk about treat to target without considering the psychological dynamic of the patient, we will not be as successful as if we integrate that into our thinking. Specifically, if a patient is doing okay but is not in remission and we, as the treating rheumatologist, want to do better, then it s easy for us. But that patient may be wedded to the status quo. That is, No, it ain t perfect, Doc, but I ve seen these ads on TV about a lot of these drugs, and they tell me about a lot of nasty things that can happen to me, so maybe the devil I know is better than the devil I don't know. Maybe I want to avoid side effects even though you re telling me I will do better. But we know that for many people, a loss is twice as important as a gain. Clearly there are gains associated with treat to target, but there are perceived losses in terms of a whole new set of side effects that I do not now have. If we are going to be successful, we have to do several things: 1) do a better job of describing the upside; 2) acknowledge the patient s fears; 3) develop trust. That trust is the key element. If we re going to establish that trust and acknowledgment that my treating physician cares, we will be more successful, I believe, in invoking the treat-to-target philosophy and utilizing it more, because we have such terrific drugs that we can use now. Let me take a minute and describe briefly the Janus kinase (JAK) signaling mechanism that we re going to be talking about for most of the conversation, and remind our audience what JAK inhibitors are and which ones are currently available for rheumatoid arthritis (RA). This molecule is bilaterally around an axis, and there are 4 alleles, or types, of it, JAK1, JAK2, JAK3, and a cousin named tyrosine kinase 2 (TYK2). These are involved in cytokine binding to surface receptors, which then activate JAK, 2018 ReachMD Page 2 of 7
3 and the JAK dimers, the JAK pairs, cause phosphorylation then activation of another partner protein called STAT, or signal transducer and activator of transcription. Those go to the nucleus after they dimerize, where they transcribe or act as transcription factors for the target genes, usually for the production of the inflammatory mediators that we seek to reduce the levels of in RA. Right now in the United States, we have 2 available JAK inhibitors. We have tofacitinib, and we have baricitinib, and these are orally dosed low molecular weight agents. It s important that they re orally dosed, and small molecules, as opposed to the biologic therapies that we ve been using. There are 2 other molecules in development in this family, upadacitinib and filgotinib, and it s thought that these 4 agents differ in terms of what their primary target is. So with that background, Joel, with the notion that we now have 2 agents available and at least 2 agents in the pipeline, give us some idea of how we are thinking about treating early RA and what, if any, the role of JAKs is going to be. My experience is, of course, primarily derived from tofacitinib. I have investigated other agents, but in terms of everyday use, tofacitinib has been around a number of years now. I think tofacitinib had a slow start, but I think people that is, prescribers began to recognize, this is a really valuable addition to our therapeutic armamentarium. I use tofacitinib a lot now in people who have failed everything, and I have migrated to using it even earlier. I think it s telling that the new American College of Rheumatology (ACR) guidelines do not distinguish between a mechanism of action that s relatively new, that has its own unique toxicities associated with it, from some of the drugs that have been around a lot longer. That is, at this point, it s really up to the doctor to determine, after a patient has failed conventional disease-modifying antirheumatic drugs (DMARDs), which drug would be best, and I think that as we gain experience with baricitinib at 2 mg and with upadacitinib, and filgotinib, which are in the wings, that the way we utilize these drugs in 2020, 2021, 2022, will evolve. My guess, because no one is perfectly prescient, is that we will be using a lot more of these drugs based upon their overall efficacy profile. Having said that, there are side effects that clearly we need to be aware of in terms of what to expect, what to monitor, and how to counsel our patients as to what they may be experiencing with these agents. Is there an order in which we should be using these drugs? Is there a particular recommended sequence? 2018 ReachMD Page 3 of 7
4 In a patient with at least moderate disease who is new to my practice and who has not been exposed to methotrexate or other biologic agents, I usually start with methotrexate and I push it to tolerance. Hopefully I use it right; I use it subcutaneously and I watch for toxicity. The data have shown that roughly a third of patients will do okay with methotrexate. Then you can add other conventional DMARDs. I love adding hydroxychloroquine to methotrexate. I think it makes a better drug. Others will go to triple therapy; I m not as big a fan of triple therapy primarily because of sulfasalazine and the frequency with which patients are unable to tolerate that. But let s say you ve ideally treated with methotrexate and hydroxychloroquine, double or triple. Now you need to move on. You need to make a decision, and that s treating to target. Which drug you use, per the ACR and European League Against Rheumatism (EULAR) guidelines, I think there s a level of arbitrariness to that choice at this point. We need real-world evidence to determine whether a patient is anti-citrullinated protein antibody positive, or seropositive, has failed prior biologic agents, all permutations and combinations of biomarkers in response, as well as age, and perhaps other biomarkers in development which of these drugs to use. It s possible that, as we gather experience from the European and US registries, that our thinking will evolve about how we use these drugs and in what order. I think that s right. I think we re leaning more toward multinational collaborations and the concept of European investigators, American investigators; you and I have done work with all of them, so it s more like a multinational collaboration leading, hopefully, to some international guidelines that can be applied regardless of the nuances of what doses are approved where. So Joel, we ve articulated great enthusiasm for this new class of agents, but we have to balance our enthusiasm over their efficacy with concerns about their safety, because no drug is without adverse events. As we ve seen in our clinical practice, these drugs may have some concerns for the class, as well as some unique concerns for the individual agents.as with any of the agents we use, with the JAK inhibitors we re concerned about infections, particularly opportunistic infections; we re concerned about tuberculosis. We re concerned about malignancy. We re concerned about potential problems with the bone marrow, inhibition of various cell-forming elements, lipid elevations, liver enzyme elevations, gastrointestinal perforations. There is no free lunch here with these agents. And that s for the class. Indeed, when it comes down to the individual agents, one of the concerns that the US Food and Drug Administration had with baricitinib, as opposed to tofacitinib, was the fact that 2018 ReachMD Page 4 of 7
5 there was an increase in thromboembolic events in the randomized controlled trials, which led to the approval of only the 2-mg dose, not the 4-mg dose. It is a sense that that adverse event may be unique to that agent, as opposed to a class effect. Certainly, there are class effects for these agents that I ve outlined, but there may be unique effects related to their profile of JAK inhibition. We don t know. We re still speculating from all of the data that we have, but clearly we have to be concerned about adverse events for the class of agents, as well as for the individual agents, and the things that require careful monitoring of these patients, whether they re being used as monotherapy or whether they re being used as combinations. We re concerned about serious infections with these agents, in particular one serious infection, herpes zoster. We ve seen an increase in herpes zoster cases in patients on the JAK inhibitors in the clinical trial and also in the postmarketing experience for them. That raises the issue of whether patients who are starting on a JAK inhibitor, whether tofacitinib or baricitinib, should be vaccinated. What s your perspective on that? My perspective is that I am concerned about zoster and my patients are concerned. Everyone has known someone who s had shingles or has seen pictures on TV and they re frightened. The killed vaccine that was most recently introduced is an excellent vaccine. My concern is the following: that it is highly adjuvanted and its adjuvanted status allows it to be more efficacious in terms of an immune response, but we re also giving patients with an autoimmune disease a strong adjuvant on 2 different occasions. So I need, personally, to see more data on safety relative to flares of an underlying autoimmune disease when patients are given an adjuvant on 2 different occasions. If I see reassuring data, I will undoubtedly use it universally. Tell us a little bit about what laboratory tests are important, how we should be monitoring patients, how often, and those kinds of things for our viewers. I think white blood cell counts, lymphocyte counts, neutrophil counts are important. Transaminase levels are meaningful. We have some rather arbitrary safety guidelines for transaminases: I ve seen 2 times normal, 3 times normal, based upon my methotrexate experience. I don t like when transaminases there are elevated at all and I tend to repeat them. If they remain elevated, I would adjust the dosage for patients on a statin and patients who are on NSAIDs. If the patient is on methotrexate, I combine methotrexate with leflunomide. I think we have more flexibility with 2018 ReachMD Page 5 of 7
6 methotrexate, and if that particular combination is used, I would back off of the methotrexate. If the transaminases remain elevated, I would probably adjust the dosage of the new agent, the JAK, so that the elevation went away. I like to get labs monthly when I use these drugs for the first time. If a patient has demonstrated that they remain in the normal range for, say, 3 months and it s arbitrary I would probably back off and see the patient at the interval dictated by their clinical status rather than by my fear of the labs. That s a very nice summary for the people who are viewing us today. Let s now switch in the last minute or two that we have to the investigative agents that are on the horizon, filgotinib and upadacitinib. Filgotinib is really interesting and it is the least far along of all. To date, perhaps the safety profile of filgotinib is favorable. We don t seem to see as many serious infections, it s true, but in fairness, I think we haven t seen the entire picture. Upadacitinib has been studied in all the categories we described before. It s clearly an efficacious drug. It seems to have all the same laboratory challenges that we ve described. However, for both of these drugs, there is no evidence of either thromboembolic disease or pulmonary emboli. But in fairness to baricitinib, I want to see how that drug does in the real world, because sparse events can occur in unpredictable patterns with any drug. I think if we can be reassured by anything regarding the new agents in development and what we ve seen so far, it is that neither the DARWIN studies of filgotinib nor the SELECT in upadacitinib have shown us any new safety signals to be concerned about that we haven t seen from tofacitinib and baricitinib. So I think that s something we can take a little bit of reassurance from. Joel, thanks a lot. Thank you. And thank you, the audience, for joining us for this CME program. Please remember to take the posttest and fill out the CME evaluation. For additional CME opportunities, please visit us at 2018 ReachMD Page 6 of 7
7 ReachMD.com, and at Announcer This activity was part of a series jointly provided by Global Education Group and Integritas Communications. To receive your free CME credit, please be sure to complete the post test and evaluation by going to ReachMD.com/ JAKInhibitors. ReachMD: Be part of the knowledge ReachMD Page 7 of 7
JAK-STAT Signaling and Disease Pathogenesis in RA and IBD
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationJAK Inhibition in Inflammatory Bowel Disease
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRheumatoid Arthritis: Challenges and Opportunities in the Evolving Treatment Landscape ReachMD Page 1 of 9
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRheumatoid Arthritis: Counseling Women Who Are Trying to Conceive
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationUnraveling Recent Cervical Cancer Screening Updates and the Impact on Your Practice
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pcsk9-antibodies-dyslipidemia-efficacy-safety-and-nonlipid-effects/8335/
More informationPatient Selection and Sequencing of Therapies in the New Melanoma Landscape
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDisease Modifying Therapies in MS: Highlights from ACTRIMS 2018
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThe HPV Data Is In What Do the Newest Updates in Screening Mean For Your Patients?
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCardiovascular Controversies: Exploring the ACC and AHA Guidelines on the Treatment of Blood Cholesterol
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRheumatoid Arthritis: Assessing Diagnostic Results in the Primary Care Setting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationA Case Review: Treatment-Naïve Patient with Advanced NSCLC: Smoker with Metastatic Squamous Cell Tumor
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRHEUMATOID ARTHRITIS
PROGRAM CONTENT AND FAQs The iq&a Interactive Medical Intelligence Zone for RHEUMATOID ARTHRITIS Focus on Established and Novel Immune-Modulating Agents: Mechanisms of Action, Optimizing Efficacy, and
More informationUncontrolled Moderate-to-Severe-Asthma: Latest Data from the Floor of CHEST 2018
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationInvestigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/origins-and-impacts-severe-neutropenia-newpharmacotherapy/9650/
More informationGenotype Testing on Current Cervical Cancer Algorithms
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCombining Individualized Treatment Options with Patient-Clinician Dialogue
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAdnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationIron Deficiency Anemia in Patients with Inflammatory Bowel Disease ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAutoimmune disorders: An emerging risk factor for CV disease
Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's
More informationPathogenesis and Management of Non-Alcoholic Fatty Liver Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pathogenesis-management-non-alcoholic-fatty-liverdisease/8155/
More informationPromising Bifunctional Agents in Immuno- Oncology: A Roundtable Discussion with the Experts
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationTargeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions Interim Outcomes Report February 2019 Gilead Sciences, Inc. Grant ID: 02669 Overview Activity Description:
More informationBefore beginning this activity, be sure to review the faculty and commercial support disclosures, as well as the Learning Objectives.
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF
Cohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF inhibitors. This is a subject of great interest to me and I
More informationThe Expanding Value of Biomarkers in NSCLC Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/closing-gaps-nsclc/the-expanding-value-of-biomarkers-in-nsclctreatment/10283/
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationResponse to Therapy ReachMD Page 1 of 8
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationHereditary Cancer Syndromes and the Obstetrician/Gynecologist
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/hereditary-cancer-syndromes-and-theobstetriciangynecologist/6990/
More informationFight-or-Flight: Understanding Our Body's Response to Adrenaline
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/primary-care-today/fight-or-flight-understanding-our-bodys-response-toadrenaline/10349/
More informationMental Health Screening: Cystic Fibrosis Foundation Guidelines and Specific Recommendations: The Benefits and Risks
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationBiologic therapy for Rheumatoid arthritis. Paul Etau Ekwom Physician and Rheumatologist
Biologic therapy for Rheumatoid arthritis Paul Etau Ekwom Physician and Rheumatologist Objectives Case presentation of patient with rheumatoid arthritis on a biologic therapy. Discuss biologic therapy
More informationWelcome to Rheumatology Highlights Report; I m Dr. Len Calabrese from the R.J. Fasenmyer Center for Clinical Immunology. And, in the next 15 minutes
Welcome to Rheumatology Highlights Report; I m Dr. Len Calabrese from the R.J. Fasenmyer Center for Clinical Immunology. And, in the next 15 minutes I m going to update you on the safety of biologics.
More informationExpert Tips for Diagnosis and Management of Bacterial Vaginosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/miscellaneous/whats-new-bacterial-vaginosis/expert-tips-for-diagnosismanagement-of-bacterial-vaginosis/9894/
More informationThe JAK/STAT Signaling Pathway and its Role in Immune-mediated Inflammatory Disease: Impact on the Treatment of RA
The JAK/STAT Signaling Pathway and its Role in Immune-mediated Inflammatory Disease: Impact on the Treatment of RA Final Outcomes Report Gilead Sciences ID: #02668 Series Overview The educational intervention
More informationA Case Review: Treatment-Naïve Patient with Head and Neck Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationInvestigating Plinabulin as Immune-Modifying Therapy for Non-Small Cell Lung Cancer (NSCLC)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/beyondspring-birnholzmita/9543/
More informationHow To Treat Resistant Bipolar Patients
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/how-to-treat-resistant-bipolar-patients/3560/
More informationDetect Cervical Cancer ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCarrier Screening in your Practice Is it Time to Expand your View?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/carrier-screening-your-practice-it-time-expandyour-view/9648/
More informationAdvances in Treatment of Moderate to Severe Psoriasis
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information2019 ReachMD Page 1 of 5
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationHold the Sunscreen: Your Body Needs that Vitamin D
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/hold-the-sunscreen-your-body-needs-that-vitamind/4149/
More informationAspirin Resistance and Its Implications in Clinical Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/aspirin-resistance-and-its-implications-in-clinicalpractice/3819/
More informationWhy the Growing Number of Hip Fracture Rates Matters
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/boning-up-on-osteoporosis/why-the-growing-number-of-hip-fracturerates-matters/10424/
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationMycoplasma Genitalium: Get to Know the Hidden STI
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/womens-health-update/mycoplasma-genitalium-get-to-know-hiddensti/9501/
More informationOlumiant (baricitinib) NEW PRODUCT SLIDESHOW
Olumiant (baricitinib) NEW PRODUCT SLIDESHOW Introduction Brand name: Olumiant Generic name: Baricitinib Pharmacological class: Janus kinase (JAK) inhibitor Strength and Formulation: 2mg; tabs Manufacturer:
More informationCAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/car-t-cell-therapy-abreakthrough-treatment-for-fighting-cancer/9859/
More informationNew Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationStatin Intolerance: Keys to Patient Counseling and Guidance
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/statin-intolerance-keys-to-patient-counseling-andguidance/7076/
More informationThe Biomechanical Approach to Heart Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/the-biomechanicalapproach-to-heart-disease/3912/
More informationCould a Daily Dose of Baking Soda Combat Autoimmune Disease?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/could-a-daily-dose-of-baking-soda-combatautoimmune-disease/10261/
More informationMetformin For Prevention of Type II Diabetes
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/metformin-for-prevention-of-type-ii-diabetes/2826/
More informationCarotid Ultrasound Scans for Assessing Cardiovascular Risk
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/carotid-ultrasound-scans-for-assessing-cardiovascularrisk/4004/
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationType1 Diabetes Cure Research & Autoimmune Diseases
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/type1-diabetes-cure-research-autoimmunediseases/1772/
More informationUsing New Guidelines to Improve Best Practices in Obesity Management
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationHypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationThe Parent's Perspectives on Autism Spectrum Disorder
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/autism-spectrum/the-parents-perspectives-on-autism-spectrumdisorder/6809/
More informationLatest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/latest-methods-earlydetection-alzheimers-cognitive-assessments-and-diagnostic-tools-practice/8321/
More informationType 1 Diabetes: Control and Cure
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/type-1-diabetes-control-and-cure/1771/
More informationWho is at Risk for Pulmonary Arterial Hypertension (PAH)?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/who-risk-pulmonaryarterial-hypertension-pah/8165/
More informationBBC LEARNING ENGLISH 6 Minute English Buttons
BBC LEARNING ENGLISH 6 Minute English Buttons This is not a word-for-word transcript Hello. This is 6 Minute English and I'm. And I'm. Today we re talking about buttons. Yes, buttons. Buttons are what
More informationAddressing Vascular Plaque Ruptures
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/addressing-vascularplaque-ruptures/3131/
More informationAddressing Barriers to Early Detection for Alzheimer's Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/addressing-barriers-earlydetection-alzheimers-disease/8322/
More informationA Critical View of JUPITER
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/a-critical-view-of-jupiter/4124/
More informationRoles of Non-HDL Cholesterol in Risk Assessment and Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/roles-of-non-hdl-cholesterol-in-risk-assessment-andtreatment/7066/
More informationWhy Are So Many Clinicians Choosing to Practice Functional Medicine?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/integrative-and-functional-medicine-in-practice/why-are-so-manyclinicians-choosing-practice-functional-medicine/8424/
More informationGlobal Perspectives on Organ Donation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-global-medicine/global-perspectives-on-organ-donation/3990/
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationThe Importance of Biomarkers in Asthma Clinical Phenotypes
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/hot-topics-in-allergy/the-importance-of-biomarkers-in-asthma-clinicalphenotypes/3889/
More informationUpdate on Psoriatic Arthritis: Best Practices in Rheumatology
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDiagnosis and Treatment of Neurosarcoidosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-neurology-and-psychiatry/diagnosis-and-treatment-ofneurosarcoidosis/3892/
More informationDisease Modifying Anti-Rheumatic Medications (DMARDS) Monitoring Clinic
Department of Rheumatology Portsmouth Hospitals NHS Trust Disease Modifying Anti-Rheumatic Medications (DMARDS) Monitoring Clinic Patient Information Leaflet Specialist Support This leaflet can be made
More informationBridging The Cardiology Gap: Care Priorities for Adults With Congenital Heart Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/bridging-cardiology-gapcare-priorities-adults-congenital-heart-disease/8031/
More information2018 ReachMD Page 1 of 10
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationGenetic Counselor: Hi Lisa. Hi Steve. Thanks for coming in today. The BART results came back and they are positive.
Hi, I m Kaylene Ready, a genetic counselor who specializes in the education and counseling of individuals at high-risk for hereditary breast and ovarian cancer syndrome. Women with an inherited BRCA 1
More informationTriglyceride-Lowering Therapies: Addressing Gaps in the Guidelines
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/triglyceride-lowering-therapies-addressing-gaps-inguidelines/8340/
More informationA Hopeful Beginning for Malaria Vaccines
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-global-medicine/a-hopeful-beginning-for-malariavaccines/4043/
More informationSickle Cell Disease: How Should YOU Reassess Management & Treatment?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/changing-conversation-sickle-cell-disease/sickle-cell-disease-howshould-you-reassess-management-treatment/10184/
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationThe Role of the Certified Diabetes Educator: A Team Effort
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/diabetes-discourse/role-certified-diabetes-educator-team-effort/7587/
More informationSmoking Cessation Strategies for the 21st Century
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/smoking-cessation-strategies-for-the-21stcentury/3862/
More informationHow a CML Patient and Doctor Work Together
How a CML Patient and Doctor Work Together Recorded on: November 5, 2012 Jessica Altman, M.D. Assistant Professor, Department of Medicine, Hematology Oncology Division Feinberg School of Medicine, Northwestern
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationWhat s the Latest in Prostate Cancer Immunotherapy Options?
What s the Latest in Prostate Cancer Immunotherapy Options? Jeri Kim, MD Associate Professor, Department of Geritourinary Medical Oncology The University of Texas MD Anderson Cancer Center Sumit K. Subudhi,
More informationInvestigating Immunotherapies for Peanut Allergy Management
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/peanutallergies/investigating-immunotherapies-for-peanut-allergymanagement/10560/
More informationNeonatal Diabetes: A Special Case of Type 1 Diabetes
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/neonatal-diabetes-a-special-case-of-type-1-
More informationExploring the Patient Journey: Let s Talk About ILD and IPF
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNHANES Database Reveals Skyrocketing Triglyceride Levels
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/nhanes-database-reveals-skyrocketing-triglyceridelevels/4075/
More informationDeveloping New Therapies to Treat Glioblastoma
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-cancer/developing-new-therapies-to-treat-glioblastoma/4077/
More informationResolving Disruptive Physician Behavior
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/resolving-disruptive-physician-behavior/3555/
More informationDeciphering Chronic Pain and Pain Medicine
Deciphering Chronic Pain and Pain Medicine Deciphering Chronic Pain and Pain Medicine Hello and welcome to Primary Care Today on ReachMD. I m your host, Dr. Brian McDonough, and I m very happy to have
More informationNews from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O.
News from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O. Please remember the opinions expressed on Patient Power are not necessarily the views
More informationCan Angioplasty Improve Quality of Life for CAD Patients?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/can-angioplasty-improve-quality-of-life-for-cadpatients/4000/
More information